• S&P 500: 1,351.95
  • Change: 0.00%
$2.31 0.00 (0%)
2/9/2012 4:00 PM

Savient Pharmaceuticals, Inc. (NASDAQ:SVNT)

CAPS Rating: 3 out of 5

A biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets.

Current Price $2.31 Mkt Cap $164.93M
Open $0.00 P/E Ratio 0.00
Prev. Close $2.30 Div. (Yield) N/A (N/A)
Daily Range $2.28 - $2.33 Volume 884,134
52-Wk Range $2.04 - $11.91 Avg. Daily Vol. 0

News & Discussion Boards

Caps

How do you think SVNT will perform against the market?

You must Sign in to MSN Caps before you can make a call.

All Players

457 Outperform
33 Underperform
 

All-Star Players

97 Outperform
13 Underperform
 

Wall Street

10 Outperform
4 Underperform
 

Top SVNT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

BuffettJunior1 (92.92)
Submitted December 17, 2011

This is not a safe investment. However, the long term growth potential from its revolutionary new drug (Krystexxa) just cannot be overlooked. At an annual price of $59,000, if Krystexxa captures even a fraction of the estimated 5 million to 8 million… More

Add Comment | Reply | Report this Post

EclecticRecluse (76.42)
Submitted November 22, 2010

Extremely High Price for Book Value

Add Comment | Reply | Report this Post
SVNT VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about SVNT.

Recs

0
Member Avatar ResearchLover (< 20) Submitted: 12/22/2011 12:54:50 AM : Outperform Start Price: $10.01 SVNT Score: -80.35

double down on SVNT based on future sales predictions of the one gout drug.

Report this Post Add Comment | Reply | Permalink

Recs

0
Member Avatar explainstuff (99.06) Submitted: 12/16/2011 10:12:33 PM : Outperform Start Price: $2.38 SVNT Score: -13.75

Market Maker Selling phase soon?

Report this Post Add Comment | Reply | Permalink

Recs

1
Member Avatar BuffettJunior1 (92.92) Submitted: 12/16/2011 9:18:52 PM : Outperform Start Price: $2.07 SVNT Score: +0.70

This is not a safe investment. However, the long term growth potential from its revolutionary new drug (Krystexxa) just cannot be overlooked. At an annual price of $59,000, if Krystexxa captures even a fraction of the estimated 5 million to 8 million U.S. gout patients, it could drive significant revenue for Savient.

Report this Post Add Comment | Reply | Permalink
View All 70 Pitches »

Leaderboard

Find the members with the highest scoring picks in SVNT.

Score Leader

BlueInsight

BlueInsight (< 20) Score: +553.68

The Score Leader is the player with the highest score across all their picks in SVNT.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		Index
Gain 		Score Commentary
Paxtor 29.17 7/13/2009 Underperform 5Y $12.92 -82.12% +54.01% +136.13 0 Comment
anticitradeshort 27.31 4/20/2009 Underperform NS $5.14 -55.06% +59.89% +114.95 0 Comment
anticitrademix 96.02 11/2/2009 Underperform 5Y $12.65 -81.74% +29.99% +111.73 0 Comment
anticitrademix2 92.68 11/2/2009 Underperform 5Y $12.65 -81.74% +29.99% +111.73 0 Comment
Halmonster64 86.49 12/7/2009 Underperform 5Y $13.64 -83.06% +22.04% +105.11 0 Comment
longtermgrowth09 68.40 8/3/2010 Underperform 5Y $13.84 -83.31% +20.34% +103.65 0 Comment
randomtask16 61.04 10/25/2010 Underperform 1Y $20.05 -88.48% +13.58% +102.05 1 Comment
shorttest4 20.58 3/8/2010 Underperform 5Y $13.89 -83.37% +18.47% +101.84 0 Comment
jroren 98.26 6/21/2010 Underperform 3M $12.89 -82.08% +19.66% +101.74 0 Comment
Asianabere 94.93 9/10/2008 Underperform 3M $19.03 -87.86% +12.76% +100.62 0 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackJMP 86.37 11/10/2011 Underperform NS $2.80 -17.50% +9.75% +27.25 0 Comment
TrackSoleil 95.78 3/4/2010 Outperform NS $14.04 -83.55% +20.37% -103.92 0 Comment
TrackOppenheimer 79.30 10/10/2009 Outperform NS $14.24 +38.62% +5.73% +32.89 9/16/2010 @ $19.74 0 Comment
TrackJefferies 86.14 8/4/2009 Underperform NS $12.10 -80.91% +36.04% +116.94 0 Comment
TrackJMP 86.37 6/17/2009 Outperform NS $12.32 -5.84% +28.21% -34.05 10/27/2010 @ $11.60 0 Comment
TrackWallStreetA 65.93 6/15/2009 Outperform NS $9.25 -75.03% +47.58% -122.60 0 Comment
TrackWedbush 86.37 6/10/2009 Outperform NS $6.11 -62.19% +45.82% -108.01 0 Comment
TrackRothCapital < 20 12/19/2008 Outperform NS $4.64 +141.16% +52.11% +89.05 5/3/2011 @ $11.19 0 Comment
TrackLeerinkSwan 87.91 11/25/2008 Outperform NS $4.20 -45.00% +58.95% -103.95 0 Comment
TrackOppenheimer 79.30 11/25/2008 Underperform NS $4.20 +193.33% +4.67% -188.66 6/17/2009 @ $12.32 0 Comment
TrackCowenandCo 81.94 10/27/2008 Underperform NS $6.70 -65.52% +61.53% +127.05 0 Comment
TrackCollinsStew 66.07 10/20/2008 Outperform NS $12.10 -80.91% +45.51% -126.42 0 Comment
TrackJefferies 86.14 4/1/2008 Outperform NS $20.42 +18.71% -6.13% +24.84 8/4/2008 @ $24.24 0 Comment
TrackDawsonJames 66.28 12/13/2007 Outperform NS $17.90 -87.09% -4.22% -82.87 0 Comment
TrackCitigroup 93.11 11/28/2007 Outperform NS $12.65 -81.74% -1.64% -80.09 0 Comment
TrackCreditSuiss 93.26 10/3/2007 Outperform NS $14.80 -84.39% -7.80% -76.59 0 Comment
TrackJimCramer 78.02 9/27/2007 Underperform 3W $15.26 -84.86% -7.36% +77.50 0 Comment
TrackCowenandCo 81.94 9/21/2007 Outperform NS $13.40 -50.00% -42.95% -7.05 10/27/2008 @ $6.70 0 Comment
TrackFerrisBaker 88.42 3/29/2007 Outperform NS $12.00 -80.75% +0.39% -81.14 0 Comment
TrackLazardCapit 78.99 2/2/2007 Outperform NS $15.00 -84.60% -0.73% -83.87 0 Comment
TrackJimCramer 78.02 1/5/2007 Outperform 3W $11.66 +30.87% +8.98% +21.89 9/28/2007 @ $15.26 0 Comment
TrackJimCramer 78.02 12/5/2006 Underperform 3W $11.84 -1.52% -0.36% +1.16 1/6/2007 @ $11.66 0 Comment

Featured Broker Partners